Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company dedicated to transforming medicines to transform lives, has scheduled its first quarter 2025 financial results conference call and webcast for May 7, 2025, at 8:00 a.m. ET.

The corporate update and financial results discussion will cover the quarter ended March 31, 2025. Interested participants can access the live audio webcast through the investor relations section at www.avadel.com. The webcast recording will remain available on the company's website for 90 days after the event.

Key Details:

• Event: Q1 2025 Financial Results and Corporate Update
• Date: Wednesday, May 7, 2025
• Time: 8:00 a.m. ET
• Access: Conference call registration required
• Registration Notice: Participants should register at least 10 minutes before the call

DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025.

A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8687

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com 
(609) 273-3162

FAQ

When will Avadel Pharmaceuticals (AVDL) report Q1 2025 earnings?

Avadel Pharmaceuticals (AVDL) will report its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:00 a.m. ET.

How can investors join Avadel's Q1 2025 earnings call?

Investors can join by registering for the conference call through Avadel's website (www.avadel.com) at least 10 minutes before the 8:00 a.m. ET call on May 7, 2025.

Where can I find the replay of AVDL's Q1 2025 earnings webcast?

The earnings webcast replay will be archived on Avadel's website (www.avadel.com) in the investor relations section for 90 days following the event.

What will be covered in Avadel's May 7 conference call?

The conference call will provide a corporate update and discuss Avadel Pharmaceuticals' financial results for the first quarter ended March 31, 2025.

How long will AVDL's Q1 2025 earnings webcast be available for replay?

The webcast replay will be available for 90 days on Avadel's website following the May 7, 2025 earnings call.